Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion

NCT07259928

Status	RECRUITING
Phase	Phase 2
Sponsor	Annexin Pharmaceuticals AB
Enrollment	12 participants

Key Eligibility Criteria

Inclusion (11)

- To be eligible to participate in this trial, an individual must meet all the following criteria:
- Must have given written informed consent (signed and dated), and any authorizations required by local law and be able to comply with all study requirements
- Male or female, e18 years of age at the time of informed consent
- Females should have no childbearing potential according to Clinical Trial Facilitation Group (CTFG) definition.
- Clear ocular media and adequate pupillary dilation in the Study Eye to permit high quality retinal imaging

... and 6 more (see full listing online)

Exclusion (40)

- An individual who meets any of the following criteria will be excluded from participation in this trial:
- General:
- Unwillingness or inability to attend all study visits and/or perform all procedures/tests/examinations, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator
- Any major medical or surgical procedure or trauma within 4 weeks prior to the day of trial intervention Treatment 1 (ANXV administration), or planned major surgery within the duration of the study through Day 120
- History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study

... and 35 more (see full listing online)

Locations (1 total)

The Retina Clinic London, London, United Kingdom